Can a brief illness perception intervention improve adherence and glycemic control in patients with type 2 diabetes?

Not Applicable

• Conditions: Metabolic and Endocrine - Diabetes; Type 2 diabetes

• Registration Number: ACTRN12620000381987
• Lead Sponsor: Professor Elizabeth Broadbent

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-03-20
• Last Update Posted: 30 March 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 126

Inclusion Criteria

Patients with poorly controlled type 2 diabetes will be included in this trial if they are (1) over 18 years of age (2) have type 2 diabetes for 1 year and longer (3) have poor glycaemic control (defined as glycosylated haemoglobin (A1c) concentration greater than or equal to 64 mmol/mol or 8% in the last two readings), and (4) are prescribed Metformin.

Any participating family members will have to be over the age of 18 years.

Exclusion Criteria

Patients will be excluded if they are (1) pregnant (2) have life-threatening illness (e.g. cancer), and (3) not prescribed Metformin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycemic control (Glycosylated hemoglobin/A1c) will be assessed at the diabetes clinic as part of standard care. HbA1c is tested using Dimension® Flex Reagent Cartridge HB1C device provided by Siemens HealthCare Diagnostic Inc (USA). It measures HbA1c based on Turbidimetric Inhibition Immunoassay (TINIA) method. [At baseline, 3 months [primary timepoint] and 6 months after baseline ];Illness perceptions will be assessed using the Arabic version of the Brief Illness Perception Questionnaire (B-IPQ) (Broadbent et al., 2006)[Baseline, post intervention [primary timepoint], 3 months and 6 months after baseline]